📊 Midday Market Take

Hey there, hope your Tuesday is treating you well, because the market certainly is. The S&P 500, Nasdaq, and Dow are all nudging higher this afternoon, with gains modest but consistent across the board.

Financials are quietly leading the charge today, with bank stocks adding a little extra color to an otherwise calm session. Keep an eye on Fed speaker commentary dropping later this afternoon, since any hint about rate timing could shake these gains loose pretty quickly.

Legend Biotech Corporation

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer.

3 Reasons to Watch LEGN

• A 100% Success Rate Stops Everyone Cold. Legend's CAR-T therapy cilta-cel just hit a 100% success rate in a clinical trial, which is the kind of number that almost never shows up in oncology research. That result is almost certainly what lit the fuse on today's 34% single-day price surge.
• In Vivo CAR-T Data Could Rewrite the Playbook. Legend is presenting early Phase 1 data for LB2501, its in vivo CAR-T candidate targeting Non-Hodgkin Lymphoma, at a major European hematology conference this week. If in vivo CAR-T works, it removes the need for the expensive personalized manufacturing process that limits how widely traditional CAR-T therapies can reach patients.
• The Chart Has Been Screaming for Three Months. The stock is up over 80% in the last 90 days, and today's jump adds another layer on top of an already remarkable run. When a biotech combines that kind of momentum with a legitimate clinical catalyst, it tends to attract a whole new wave of institutional attention.

Top Market Headlines

S&P 500 Quant Leaders: 5 Top Stocks Averaging 133% Forward EPS Growth

Less than 10% of S&P 500 stocks have Strong Buy Quant Ratings.

95% of SpaceX profits are already gone (Ad)

By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billion - you'd be buying at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's path, still priced like Wall Street hasn't noticed. It powers the infrastructure Musk's operation can't run without. Dylan Jovine is naming the ticker free - before the June S-1 closes the window.

Drone Stocks Soar As Pentagon Considers Funding, Including a Trump

Drone stocks just caught a bid after investors reacted to a Wall Street Journal report that the Trump administration is in talks to fund multiple U.S.

Buy 3 Momentum Anomaly Stocks as Tech Rally Spurs Fresh Highs

CMPR, MTSI and LITE pick up momentum interest as a tech-led AI rally lifts U.S. stocks to fresh highs.

Elon's $480 Trillion Currency Masterplan (Ad)

He's waited 27 years for this moment. Elon Musk just launched his biggest disruption ever, which could totally reset how millions of people access their money and even pay tax.

Top 25 High-Yield Dividend Stocks For June 2026

My updated dividend stock screening highlights 25 U.S.

President Trump could be about to make this overlooked ticker soar (Ad)

For years this ticker has been ignored and overlooked. But Larry Benedict — the hedge fund legend who went 20 years without a losing year — says Trump's "Project 2026" could send it on a rally. He predicts hundreds of billions of dollars are about to flow into this single opportunity. It's not AI. Not chips. Not a resource stock.